Natco Gets Emergency Use Nod For Baricitinib To Treat Covid-
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Generic drugmaker Natco Pharma announced that it has received emergency use approval for Baricitinib tablets from the Central Drugs Standard Control Organisation, the drug regulator in India. In a statement, the Hyderabad headquartered pharma company said Baricitinib in combination with Remdesivir is used for the treatment of Covid-19 patients.

The US Food and Drug Administration had in November last year issued an emergency use authorisation for the drug Baricitinib in combination with Remdesivir for the treatment of suspected or laboratory-confirmed Covid-19 in hospitalised patients requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (Ecmo).

Baricitinib is a prescription oral tablet medication approved and sold under the brand name Olumiant by Eli Lilly for the treatment of moderately to severely active rheumatoid arthritis. Natco said it will be requesting a compulsory license based on emergency use and in the light of the grave and serious public health emergency across the country owing to the pandemic.

The generic drugmaker said it is ready to launch the product this week aimed at making the product available to suffering patients across India.

Source:
https://health.economictimes.indiatimes.com/news/pharma/natco-gets-emergency-use-nod-for-baricitinib-to-treat-covid-19/82366158
4 shares
Like
Comment
Share